

**Daclatasvir**

| Section                                                                                                                                                         | Indications         |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations<br>Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride) | Chronic hepatitis C |

**Daclatasvir + sofosbuvir**

| Section                                                                                                       | Indications         |
|---------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations<br>Oral > Solid: 60 mg + 400 mg | Chronic hepatitis C |

**Dasabuvir**

| Section                                                                                                          | Indications         |
|------------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations<br>Oral > Solid: 250 mg tablet | Chronic hepatitis C |

**Elbasvir + grazoprevir**

| Section                                                                                                           | Indications         |
|-------------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations<br>Oral > Solid: 50 mg + 100 mg | Chronic hepatitis C |

**Entecavir**

| Section                                                                                                                                           | Indications         |
|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors<br>Oral > Liquid: 0.05 mg per mL<br>Oral > Solid: 0.5 mg; 1 mg | Chronic hepatitis B |

**Glecaprevir + pibrentasvir**

| Section                                                                                                                                      | Indications         |
|----------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations<br>Oral > Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules | Chronic hepatitis C |

## Ledipasvir + sofosbuvir

### Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 90 mg + 400 mg tablet

### Indications

Chronic hepatitis C

## Ombitasvir + paritaprevir + ritonavir

### Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

### Indications

Chronic hepatitis C

## Pegylated interferon alfa (2a)

### Section

Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

### Indications

Chronic hepatitis C

## Pegylated interferon alfa (2b)

### Section

Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

### Indications

Chronic hepatitis C

## Ravidasvir

### Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid > tablet: 200 mg

### Indications

Chronic hepatitis C

## Ribavirin

### Section

Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution

Oral > Solid: 200 mg; 400 mg; 600 mg

### Indications

Chronic hepatitis C

## Simeprevir

### Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations  
Oral > Solid: 150 mg

### Indications

Chronic hepatitis C

## Sofosbuvir

### Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations  
Oral > Solid: 400 mg; 200 mg

### Indications

Chronic hepatitis C

## Sofosbuvir + velpatasvir

### Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations  
Oral > Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet

### Indications

Chronic hepatitis C

## Tenofovir alafenamide

### Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Solid: 25 mg

### Indications

Chronic hepatitis B

## Tenofovir disoproxil fumarate

### Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

### Indications

Chronic hepatitis B